

# Ming Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4335637/publications.pdf>

Version: 2024-02-01

88  
papers

5,346  
citations

136740

32  
h-index

91712

69  
g-index

91  
all docs

91  
docs citations

91  
times ranked

6292  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 150-160.	0.8	137
2	A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 95.	1.8	8
3	Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	0.6	2
4	Reply to J. Mei et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200020.	0.8	0
5	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 226-244.	2.0	4
6	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 73-77.	0.9	1
7	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	1.4	91
8	Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 618206.	1.3	53
9	Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 167-176.	1.8	30
10	Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 253-261.	1.8	2
11	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3207-3216.	2.0	21
12	Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619461.	1.3	14
13	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1267-1276.e1.	0.2	24
14	Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. <i>European Journal of Radiology</i> , 2021, 142, 109890.	1.2	4
15	Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 631-645.	0.7	15
16	Cell-adaptable dynamic hydrogel reinforced with stem cells improves the functional repair of spinal cord injury by alleviating neuroinflammation. <i>Biomaterials</i> , 2021, 279, 121190.	5.7	53
17	Identification of the Pyroptosis-Related Gene Signature for Overall Survival Prediction in Patients With Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 742994.	1.8	14
18	Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro. <i>Cancer Cell International</i> , 2021, 21, 610.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 787-797.	3.3	23
20	Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1605-1618.	1.6	38
21	Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply. <i>JAMA Oncology</i> , 2019, 5, 1806.	3.4	4
22	Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 78-83.	0.2	7
23	NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 228.	1.8	25
24	Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4200-4213.	1.3	9
25	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. <i>JAMA Oncology</i> , 2019, 5, 953.	3.4	292
26	Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 1430-1437.	0.4	23
27	Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. <i>FASEB Journal</i> , 2019, 33, 8759-8770.	0.2	54
28	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 349-357.e2.	0.2	21
29	Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus. <i>Metabolomics</i> , 2019, 15, 156.	1.4	10
30	NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>International Journal of Cancer</i> , 2019, 145, 662-670.	2.3	26
31	Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 665-671.	1.2	13
32	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 60-69.	1.8	153
33	Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 734-743.	0.9	35
34	Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. <i>Cancer Communications</i> , 2018, 38, 1-12.	3.7	92
35	Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. <i>Cancer Medicine</i> , 2018, 7, 5339-5350.	1.3	25
36	Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 475-482.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1068-1077.e2.	0.2	19
38	CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. <i>Oncogene</i> , 2018, 37, 6025-6040.	2.6	211
39	Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3043-e3043.	2.7	25
40	MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 263-273.	1.2	21
41	Prognostic significance of sodium-potassium ATPase regulator, FXYP3, in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 15, 3024-3030.	0.8	11
42	Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2025-2032.	0.9	13
43	Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. <i>Chinese Journal of Cancer</i> , 2017, 36, 83.	4.9	90
44	Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 3122.	1.4	22
45	Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4239-4246.	1.0	18
46	GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0168907.	1.1	79
47	MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 1227-1239.	3.6	29
48	Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2465-2476.	1.1	13
49	MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. <i>Cancer Letters</i> , 2016, 383, 85-93.	3.2	66
50	Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. <i>British Journal of Cancer</i> , 2016, 115, 1039-1047.	2.9	20
51	Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. <i>Liver International</i> , 2016, 36, 1516-1524.	1.9	1
52	Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. <i>Chinese Journal of Cancer</i> , 2016, 35, 28.	4.9	26
53	Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. <i>European Radiology</i> , 2016, 26, 2078-2088.	2.3	33
54	Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. <i>Oncotarget</i> , 2016, 7, 38845-38856.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. <i>Chinese Journal of Cancer</i> , 2015, 34, 205-16.	4.9	17
56	EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 63, 863-873.	1.8	65
57	A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. <i>Oncology Letters</i> , 2015, 10, 2787-2794.	0.8	6
58	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 63, 122-130.	1.8	101
59	Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 41.	1.8	27
60	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 837-843.	0.6	21
61	The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 5990-6000.	0.8	23
62	Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 35116-35128.	0.8	29
63	A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 928-936.	1.3	70
64	Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. <i>Medical Oncology</i> , 2013, 30, 696.	1.2	21
65	Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4780-4791.	3.2	95
66	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 580-581.	3.0	0
67	Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 595-604.	1.9	78
68	Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 59-68.	3.0	64
69	Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2013, 8, e60444.	1.1	58
70	Radiofrequency Ablation versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas 2 cm or Smaller: A Retrospective Comparative Study. <i>Radiology</i> , 2012, 262, 1022-1033.	3.6	203
71	An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 313-321.	1.8	41
72	Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. <i>Journal of Translational Medicine</i> , 2012, 10, 245.	1.8	19

#	ARTICLE	IF	CITATIONS
73	Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e44061.	1.1	13
74	Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2011, 22, 702-709.	0.2	106
75	Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatology Research, 2011, 41, 553-563.	1.8	42
76	Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 866-874.	1.4	28
77	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Annals of Surgical Oncology, 2011, 18, 413-420.	0.7	305
78	Hepatic Resection versus Transarterial Lipiodol Chemoembolization as the Initial Treatment for Large, Multiple, and Resectable Hepatocellular Carcinomas: A Prospective Nonrandomized Analysis. Radiology, 2011, 259, 286-295.	3.6	58
79	Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatology International, 2010, 4, 537-547.	1.9	33
80	LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 2046.	1.4	13
81	Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World Journal of Gastroenterology, 2010, 16, 264.	1.4	46
82	A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1437-1445.	1.2	122
83	High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Human Pathology, 2009, 40, 381-389.	1.1	191
84	The Surgical Margin in Liver Resection for Hepatocellular Carcinoma. Annals of Surgery, 2007, 246, 691-692.	2.1	1
85	Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma. Annals of Surgery, 2007, 245, 36-43.	2.1	424
86	Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. Gastroenterology, 2007, 132, 2328-2339.	0.6	743
87	Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 547-555.	1.2	60
88	Micrometastases of Solitary Hepatocellular Carcinoma and Appropriate Resection Margin. World Journal of Surgery, 2004, 28, 376-381.	0.8	150